Tuesday, November 29, 2011

Felicity Jones is the new face of Dolce & Gabbana



By Kimberley Foster

One of my favourite young British actresses has just landed a major contract with Dolce & Gabbana. Felicity Jones, star of Like Crazy and Chalet Girl, will become the new ambassador for Dolce & Gabbana The Make Up.

The 28-year-old will star in the brand's Kohl Collection campaign which will be released in January. Jones will portray an "an aristocratic, sauvage girl" in the ads, which doesn't really reveal a lot at this stage.

In a joint statement, the designers said: "representing a heady mix of sensuality, confidence and beauty, Felicity Jones offers a sense of divine contradiction. Classically beautiful yet modern in attitude, her audacious gaze is impossible to ignore."

Of course Felicity is no stranger to modelling. She has also starred in the Autumn/Winter 2011 campaign for Burberry alongside a host of other famous models, actors and musicians.

For more beauty news and reviews, check out Kiss and Makeup.

[via WWD]




Read more!

British Fashion Awards 2011


Victoria Beckham,Marc Jacobs,Kate Moss


model Jade Parfitt follows suit


Model Poppy Delavigne provides some much-needed colour in Matthew Williamson


Colin Firth and his wife Livia, continuing her Green Carpet Challenge in Henrietta Ludgate


Supermodel Kate Moss makes even a string bag look good

Samantha Cameron sports a pair of £590 Charlotte Olympia heels for the occasion


Alexa Chung not only wears Christopher Kane but poses with him too, after the designer won the New Establishment award

Victoria Beckham clutches her award for best Designer Brand

Stella McCartney, right, wins the Red Carpet award, but poses on a blue one with friend Kate Hudson


Alexander McQueen's Sarah Burton, the woman behind 'that' wedding dress, poses with her Designer of the Year award at the Savoy Hotel
A model presents a creation by British designer Stella McCartney as part of her Spring/Summer 2012 women's ready-to-wear fashion collection in Paris

Models present creations by British designer Stella McCartney as part of her Spring/Summer 2012 women's ready-to-wear fashion collection in Paris


Models present creations by Stella McCartney


Models for Stella McCartney

British Fashion Awards 2011 list of winners:

Designer of the Year: Sarah Burton for Alexander McQueen
New Establishment Award: Christopher Kane
Isabella Blow Award for Fashion Creator: Sam Gainsbury of Gainsbury and Whiting
Red Carpet Award: Stella McCartney
Designer Brand Award: Victoria Beckham
Emerging Talent, Ready-to-Wear: Mary Katrantzou
Emerging Talent, Accessories: Tabitha Simmons
Emerging Talent, Menswear: Christopher Raeburn for Louis Vuitton
Menswear Designer: Kim Jones
Model Award: Stella Tennant
Accessory Designer of the Year: Charlotte Delall for Charlotte Olympia
Outstanding Achievement in Fashion: Paul Smith
British Style Award: Alexa Chung




Read more!

Aggressive Prostate Cancers May Be Found With Gene Screening

By Elizabeth Lopatto - Nov 29, 2011 3:37 AM GMT+0700

Scientists measuring active DNA in prostate tumors have identified aggressive forms of the disease that are about three times more likely to kill patients within a few years, a study shows.

Screening for the genes, found in about 29 percent of patients in the study, may allow the most lethal types of prostate cancer to be pinpointed earlier and more definitively than current tests, researchers said today in a report in the Proceedings of the National Academy of Sciences.

More than 240,800 U.S. men will be diagnosed with prostate cancer this year and 33,700 will die, according to the National Cancer Institute. In some instances, it can take 10 years for the cancer to spread, spurring some doctors to advise watchful waiting for men older than 75 rather than immediate treatment that can include surgery. In other cases, the disease can move quickly, killing within a few years.

“We’ve begun the process of identifying genes which predispose poor outcomes,” said Arnold Levine, a study author and biologist at the Institute for Advanced Study in Princeton, New Jersey. “It’s an early indication.”

The study used data from 281 patients from Sweden who had been recruited between 1977 through 1999 that included their age, whether they died from the cancer and how long they survived. The scientists tested their tumor tissue for genetic expressions associated with prostate cancer.

“Stem-cell-like” gene activation patterns examined in the new test led researchers to identify two subtypes of prostate cancer that carried a 3.2-fold increased risk of death.

Gleason Score

The current method for predicting prostate cancer involves a method of tumor grading based on how the malignant cells pattern themselves, called the Gleason system. Patients’ tumors are scored on the cell patterns, which are rated by their ability to mimic normal prostate gland structure. A low score means the cancer is similar to normal prostate tissue and is less likely to spread, whereas a high score means the cancer is more likely to spread, portending a poorer outcome.

A low Gleason score, however, doesn’t necessarily mean the cancer won’t turn hostile, researchers said. The gene test may help predict patients with low Gleason scores who will have poor survival, they said.

The results will need to be validated in a larger prospective trial, Levine said. His group has started that work. Early data may be available as soon as five years from now, and survival data in 10 to 15 years, he said.

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.



Read more!

Onyx Pharmaceuticals Said to Weigh Sale



Bottles and tablets of Onyx Pharmaceuticals' Nexavar kidney and liver cancer treatment. Source: Onyx Pharmaceuticals via Bloomberg
By Sasha Damouni and Jeffrey McCracken - Nov 29, 2011 7:02 AM GMT+0700

Onyx Pharmaceuticals Inc. (ONXX), the developer of the kidney-cancer treatment Nexavar, is exploring options, including a possible sale, said two people with knowledge of the matter.

Potential buyers are studying Onyx’s business and its experimental carfilzomib cancer therapy, said one of the people who declined to be identified as the discussions are private. Onyx, based in South San Francisco, California, had a market value of about $2.4 billion as of Nov. 25 and is working with Centerview Partners LLP to review alternatives, said the people.

Onyx gave itself more strategic options last month when it settled a lawsuit with Bayer AG (BAYN) over the experimental cancer medicine regorafenib and amended its collaboration agreement for Nexavar, said Jim Birchenough, an analyst at Bank of Montreal. (BMO) The Oct. 11 agreement relieves Onyx from any future development or commercialization costs for regorafenib.

“With the elimination of that change-of-control provision any third-party acquirer now would get full economics to Nexavar and regorafenib,” Birchenough said. “Carfilzomib would be of interest to large pharma, but that interest may be expressed by partnership as opposed to M&A.”

The deal with Leverkusen, Germany-based Bayer includes a 20 percent royalty payment on future sales of regorafenib for Onyx, or its acquirer. The drug may generate $106 million by the end of 2014, according to analysts. Potential buyers of Onyx also retain 50-50 profit sharing rights to Nexavar, which could hit $518.2 million in sales this year, according to the average estimate of six analysts in a Bloomberg survey.

Shares Rise

Onyx gained 14 percent to $42.80 at the close in New York, for the company’s biggest single-day increase since July 2010.

After today’s jump, Onyx trades at 9.7 times trailing 12- month sales, while the median biotech deal in the last five years was valued at about 5.4 times, according to data compiled by Bloomberg.

Regulators are reviewing Onyx’s carfilzomib, which treats multiple myeloma, a cancer of plasma cells. The Food and Drug Administration is due to decide soon whether to accept Onyx’s filing for accelerated approval, leading to a possible marketing clearance date of March 28, Birchenough said.

“I would think that any potential acquirer would want to see the outcome of carfilzomib regulatory review,” said Howard Liang, an analyst at Leerink Swann & Co. in Boston. “We are only a few months away.”

Carfilzomib may generate $241.7 million in sales by the end of 2014, according to the average estimate of three analysts surveyed by Bloomberg.

Onyx reported a net loss of $84.9 million in 2010 and has reported an annual profit twice since 1996 when it first offered shares to the public. The company had $324.5 million in revenue last year.

Lori Melancon, a spokeswoman for Onyx, declined to comment, as did a spokeswoman for Centerview. No deal is certain and the business review is still at a preliminary stage, the people said.

To contact the reporters on this story: Sasha Damouni in New York at sdamouni2@bloomberg.net; Jeffrey McCracken in New York at jmccracken3@bloomberg.net

To contact the editor responsible for this story: Jennifer Sondag at jsondag@bloomberg.net



Read more!

Monday, November 28, 2011

Celebrity Style : Selena Gomez

















Read more!

Rachael Weisz speaks on Andrew Marr Show

Actress Rachel Weisz speaks on the BBC's Andrew Marr Show in London November 27, 2011. The interview was recorded on November 25, and broadcast on Sunday.[Photo/Agencies]

Actress Rachel Weisz speaks on the BBC's Andrew Marr Show in London November 27, 2011. The interview was recorded on November 25, and broadcast on Sunday.[Photo/Agencies]

Actress Rachel Weisz speaks on the BBC's Andrew Marr Show in London November 27, 2011. The interview was recorded on November 25, and broadcast on Sunday.[Photo/Agencies]

Actress Rachel Weisz speaks on the BBC's Andrew Marr Show in London November 27, 2011. The interview was recorded on November 25, and broadcast on Sunday.[Photo/Agencies]


taken from : China Daily

Read more!

Friday, November 25, 2011

Spring 2012 Trend: Spin a Yarn

By Kim Friday and Catherine Peridis


Magda Berliner’s cotton shorts and Skies Are Blue’s linen and metallic thread sweater. Kimberly Baker necklace and ring; Pretty Ballerina shoes.
Photo by George Chinsee


Again
Photo by Robert Mitra


Diana Broussard
Photo by Robert Mitra


Ralph Lauren Collection
Photo by Robert Mitra


Rag & Bone
Photo by Robert Mitra



Dennis Basso
Photo by Robert Mitra


Timo Weiland
Photo by Robert Mitra


Funktional
Photo by Robert Mitra


Threeasfour
Photo by Robert Mitra


Funktional
Photo by Robert Mitra


Love Sani
Photo by Robert Mitra


taken from : wwd

Read more!

Thursday, November 24, 2011

'Amelie' lights up Champs Elysees

French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

Environmentally-friendly holiday lights hang from the lower branches of trees to decorate the Champs Elysees in Paris as rush hour traffic fills the avenue leading up to the Arc de Triomphe November 23, 2011.[Photo/Agencies]

French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

Paris Mayor Bertrand Delanoe (L) and French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

Paris Mayor Bertrand Delanoe (L) and French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

French actress Audrey Tautou attend the official lighting ceremony of holiday decorations along the Champs Elysees in Paris November 23, 2011.[Photo/Agencies]

taken from : China Daily

Read more!

Justin Bieber performs on 'Today' show

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber hugs Usher (R) after performing on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singers Justin Bieber and Usher (L) perform together on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singers Justin Bieber and Usher (R) pose together after performing on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singers Justin Bieber (R) and Usher (L) perform together on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

Singer Justin Bieber performs on NBC's "Today" show in New York November 23, 2011.[Photo/Agencies]

taken from : China Daily

Read more!